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viability of cells present in surgical samples of degenerate intervertebral
disc tissue.
Methods: The technique for live/dead differentiation of cells used in this
study utilises the ﬂuorescent probes chloromethyl ﬂuorescein diacetate
(CMFDA) and ethidium homodimer (EH). Samples of herniated discs were
obtained from patients undergoing routine discectomy and processed
within 2 hours of excision. A small piece of each sample, approximately
5mm2, was incubated in 1ml of 25mM CMFDA/2mM EH solution in the
dark for 2 hours at 37°C. The tissue was then blotted dry and snap frozen.
Cryosections were taken at various points throughout the thickness of the
tissue sample, mounted with Vectashield containing DAPI and visualised
with a ﬂuorescent microscope. Cell viability was analysed by counting
at least 200 cells from a minimum of ﬁve ﬁelds of view.
Results: To date 21 surgical disc samples from patients, aged 17–57 years,
have been examined. Preliminary results show that greater than 80%
of cells are alive after excision. Cells in these discs commonly occur
in clusters (approximately 54% of disc cells are clustered). Clustered
cells exhibited a higher proportion of live cells compared to single cells
within the same tissue section, e.g. 93% of clustered cells were viable
compared to 82% of single cells. Cell viability appeared consistent across
all locations of the disc samples. Dead cells, when they did occur, were
predominantly seen around the periphery of the disc sections which
may be derived from trauma during dissection.
Conclusions: In contrast to reports in the literature, these results indicate
that the viability of cells from the herniated disc may be adequate
to consider for utilising in biological therapies. Interestingly, a greater
proportion of clustered cells appear to be viable compared to single cells.
Additionally we plan to investigate whether there is any relationship
between cell viability and the pathology, duration of symptoms or age of
patient, as this may serve as an indicator of the suitability of degenerate
discs for cell therapy.
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Purpose: Biology offers several strategies for restoring the degenerating
disc, including the use of natural proteins that increase matrix
accumulation and assembly, enhance the number of disc cells, or in other
ways lead to restoration of the native healthy disc. This is the basis for
administering Orthokine-derived Autologous Conditioned Serum (ACS) a
new treatment method that not only supplies with a pharmaceutical
monosubstance but with nutrients, anti-inﬂammatory cytokines and
several growth factors.
When peripheral blood is withdrawn and incubated with etched glass
beads, leukocytes within the aspirate enrich the plasma with anti-
inﬂammatory cytokines, such as IL-1Ra, as well as growth factors,
including PDGF, FGF-2, TGFb, IGF and HGF. After centrifuging and ﬁltering,
the ACS is returned locally to the affected region. It has been used
successfully, by way of local injection, for the treatment of human and
equine osteoarthritis, after ACL-reconstructive surgery and radiculopathy
(see references).
Methods: A non-blinded, prospective study was conducted to evaluate
feasibility and efﬁcacy of ACS injections in patients suffering from lumbar
disc pain (veriﬁed by anamnesis and clinics, MRI scan and distension
tests, no relieve after 8 weeks of well conducted conservative treatment,
pain reduction less than 50% VAS, after periradicular inﬁltration
procedures). 19 patients had a discography and three intradiscal
injections of ACS once per week for three consecutive weeks and were
followed for six months. Outcome was measured by patient administered
outcome instruments (VAS, ODI).
Results: Patients with showed a clinically remarkable and signiﬁcant
reduction in pain and disability after the ACS injection series. Mean
improvement was 58% in VAS. 11 out of 19 patients reported at least
50% pain improvement. No serious side effects occurred. There were no
infections in this series.
Conclusions: Although, these results must be conﬁrmed in larger clinical
trails and with objective assessments like quantitative MRI scans, the use
of ACS in the intervertebral disc could be worthy of consideration given
its impressive safety record and rich mixture of growth factors, cytokine
antagonists, and, possibly, additional helpful agents.
Fig. 1. ACS Production 1.1–1.5. For the ACS preparation whole blood
is drawn using special syringes (Orthokine EOT Syringe, Orthogen,
Duesseldorf, Germany) with increased inner surface area (1). While
the blood is incubated for six to nine hours (2), peripheral blood
leukocytes reproducibly produce elevated amounts of endogenous anti-
inﬂammatory cytokines. Following centrifugation and extraction (3+4),
autologous conditioned cell free serum (ACS) is then portioned (5) and
either stored until needed at minus 18° Celsius or directly injected into
the affected disc, joint or spinal region of the patient.
Table 1. Cytokines and growth factors present in autologous conditioned
serum (ACS) produced using the 10ml Orthokine system.
Mean
IL-1Ra 2015 pg
IL-6 28.7 pg
IL-10 33.4 pg
FGF b 27 pg
VEGF 509 pg
HGF 1,339 pg
IGF1 117,209 pg
PDGG AB 39,026 ng
TFG b 97,939 ng
Abbr.: IL-1Ra = interleukin-1 receptor antagonist; IL-6 = interleukin-6;
IL-10 = interleukin-10; FGFb = ﬁbroblast growth factor-b; VEGF = vascular
endothelial growth factor, HGF = hepatocyte growth factor; IGF1= insulin-
likegrowth-factor-1; PDGF = platelet derived growth factor, TGF-b =
transforming growth-factor-b. There is no noticeable induction of the
proinﬂammatory IL-1b or TNF-a. Measurements from ELISA kits (R&D
Systems).
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Introduction: Supraspinatus tendon (SE) is an essential structure for
the proper function of rotator cuff and it is the most frequently tendon
affected in the case of rotator cuff tears. Common surgical procedures
to repair SE lesions are often unsatisfactory due to the inadequate
recovery. Regenerative medicine is one of the most promising techniques
to improve these treatments by taking advantage of the regenerative
potential of mesenchymal stem cells (MSCs).
The aim of this study was to evaluate, in an experimental rat model, the
effectiveness of recovery after surgical treatment using MSCs embedded
in collagen type I vehicles.
Methodology: A chronic rotator cuff tear model was developed detaching
at the insertion site the SE of adult Sprague-Dawley rats (9 months old),
n = 4.
One month post-injury, the tendon was sutured with a type I collagen
vehicle with or without MSCs. One million cells, previously obtained
from the femoral channel of age matched rats were embedded in type I
collagen gel (n = 4) or attached to type I collagen membranes (n =4). In
parallel, a control group was treated only with the vehicle type I collagen
gel (n = 4) or with type I collagen membrane (n =4), free of cells.
Recovery was evaluated for each specimen three months after injury
determining the biomechanical strength (Newtons, N) of the tendon-
humerus interface (Instron). The contralateral shoulder was used as a
